Table 5

Distribution of immunohistochemical characteristics in familial non-BRCA1/2 tumors and control group

Non-BRCA1/2 n (%)PControl group (IDCs) n (%)
Grade
 114 (50)10 (20.8)
 28 (28.6)15 (31.3)
 36 (21.4)0.01823 (47.9)
ER
 Negative7 (25.0)15 (31.3)
 Positive21 (75.0)NS33 (68.8)
PR
 Negative9 (32.1)22 (44.9)
 Positive19 (67.9)NS27 (55.1)
BCL2
 Negative12 (44)26 (54.2)
 Positive15 (55.6)NS22 (45.8)
Ki-67
 0–5%25 (92.6)26 (53.1)
 6–25%2 (7.4)18 (36.7)
 >25%00.0025 (10.2)
P53
 Negative26 (96.3)33 (68.8)
 Positive1 (3.7)0.00515 (31.3)
HER-2 (IHC)
 Negative (0/+)26 (96.3)36 (73.5)
 Positive (++)04 (8.2)
 Positive (+++)1 (3.7)0.0009 (18.4)
E-CD
 Preserved12 (42.9)32 (68.1)
 Reduced16 (57.1)0.03215 (31.9)
P-CD
 Absent29 (100)44 (93.6)
 Present0NS3 (6.4)
β-catenin
 Preserved6 (21.4)30 (65.2)
 Reduced22 (78.6)0.00016 (34.8)
γ-catenin
 Preserved6 (21.4)13 (28.3)
 Reduced22 (78.6)NS33 (71.4)
p120ctn
 Preserved7 (25.9)17 (37.0)
 Reduced20 (74.1)NS24 (63.0)
HER-2 a
 Negative20 (95.2)37 (80.5)
 Positive1 (4.8)NS9 (19.5)
c-MYC a
Negative14 (87.5)31 (68.9)
Positive2 (12.5)NS14 (31.1)
  • a By FISH analysis.